India Records 699 New COVID Cases, Bringing the Total to 6,559

India Records 699 New COVID Cases, Bringing the Total to 6,559

India continues to see a sharp increase in COVID-19 cases, with the nation recording 699 new infections in the previous day, according to statistics provided on Tuesday by the Union Health Ministry. The Covid case total has increased to 4.46 crore with the most recent additions (4,46,96,984).

According to the most recent statistics, there are now 6,559 active cases, and two additional fatalities bring the total number of deaths to 5,30,808. Odisha reported one fatality, while Kerala reconciled another. The percentage of active infections is at 0.01 percent.

Moreover, the weekly optimism was 0.91 percent, while the daily positivity was 0.71 percent. The government said that the national COVID-19 recovery percentage was 98.80%.

97,866 tests for the detection of Covid have been performed in the previous 24 hours, bringing the total number of tests for this purpose to 92.04 billion.

4,41,59,617 persons have recovered from the illness, while the case fatality rate has been reported at 1.19 percent. On the nation as a whole, the Covid vaccine has been given out in doses totaling 220.65 crore, according to the ministry's website.

The Center updated its recommendations for treating adult coronavirus patients on Sunday, saying that antibiotics shouldn't be used in instances of Covid unless there is a clinical suspicion of bacterial infection.

The updated recommendations, released in response to an increase in coronavirus infections, advised against treating adult COVID-19 patients in India with medications such hydroxychloroquine, molnupirvir, favipirvir, azithromycin, and doxycycline.

The clinical guideline protocol was revised during a meeting of the AIIMS/ICMR-COVID-19 National Working Group on January 5. Also, it has cautioned physicians against using convalescent plasma treatment.

"Until there is a clinical suspicion of bacterial illness, antibiotics should not be utilized. The recommendations said that the possibility of COVID-19 co-infection with other endemic illnesses must be taken into account.

Remdesivir may also be taken into consideration for up to five days in moderate or severe disorders that are very susceptible to progressing. When a patient has moderate to severe illness with a high likelihood of progression and needs supplementary oxygen but is not on IMV or ECMO, it should be begun within 10 days of the beginning of symptoms.

The medication should not be given for more than five days and should not be administered at home or on patients who are not receiving oxygen assistance, according to the recommendations.